Clinical Trial Search

Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants

Primary: Overall Response Rate — .083 proportion of participants

Primary: Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer. — 2; 7; 16; 21 participants

Primary: Objective Tumor Response — 4; 8; 8; 32 Participants

Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants

Primary: Progression-free Survival Rate After 6 Months of Treatment on Study — 0 participants

Primary: Progression-free Survival (PFS) at 6-months — 28 percentage of participants

Primary: Complete and Partial Response Rate Using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 2; 11; 1; 8 participants

Primary: Overall Response Rate (ORR) — 4 participants

Primary: Objective Tumor Response — 21; 32; 17; 1 participants

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST) — 12.4; 8.4 Months — p=<0.0001

Primary: Six Month Progression Free Survival (PFS) — 43.9 percentage of participants

Primary: Clinical Response Benefit (Modified Gynecologic Cancer InterGroup [GCIG] Cancer Antigen [CA]-125 Response or Stable Disease) Based on the Response Evaluation Criteria in…

Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants

Primary: Number of Participants Assessed for Safety and Tolerability as Assessed by NCI CTCAE v3.0 — 3; 3; 4; 2 Participants

Primary: Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria — 9; 0 participants

Primary: Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or…

Primary: Objective Response Rate (ORR) — 2; 0 Participants

Primary: Dose Limiting Toxicity (DLT) — 2; 3; 4 Dose Limiting Toxicities

Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…

Primary: Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 3.6 percentage of evalubale patients

Primary: Progression-free Survival (PFS) — 56 percentage of participants

Primary: Nature and Degree of Toxicity — 2; 4; 20; 19 Participants

Primary: Median Progression-free Survival — 3.2; 4.5 months

Primary: Tumor Response — 23.4 Percentage of participants

Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants

Primary: Progression Free Survival (PFS) Rate at 6 Months — 55.2 percentage of patients